DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506007-26-00

Acronym

1438-0009

Enrollment

Registered

2023-12-11

Start date

2024-01-15

Completion date

Unknown

Last updated

2025-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026